Poland· PL-100199642
Figura 1
A medicinal product containing sennae foliolum, registered in Poland by Zakłady Farmaceutyczne POLPHARMA S.A..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Sennae foliolum
- Manufacturer
- Zakłady Farmaceutyczne POLPHARMA S.A.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991037826
- gtin05909991037819
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aefeedf4-ddcb-4279-b654-dab55a3169fc GET /v1/drugs/aefeedf4-ddcb-4279-b654-dab55a3169fc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Zioła do zaparzania w saszetkach",
"source": "urpl",
"strength": "16,58-22,43 mg glikozydów hydroksyantracenowych w przeliczeniu na sennozyd B/saszetkę",
"packaging": "05909991037826 ¦ OTC ¦ 22668\n30 sasz. 3 g\n05909991037819 ¦ OTC ¦ 45987\n20 sasz. 3 g",
"substance": "Sennae foliolum -",
"common_name": "Sennae foliolum",
"pl_product_id": "100199642",
"pozwolenie_nr": "10378",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about sennae foliolum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.